Placebo effects in neurologic disease:
Gespeichert in:
| Weitere Verfasser: | , , |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Cambridge, MA ; San Diego, CA
Academic Press, an imprint of Elsevier
2020
|
| Ausgabe: | First edition |
| Schriftenreihe: | International review of neurobiology
volume 153 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | xii, 266 Seiten Illustrationen |
| ISBN: | 9780128211182 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV046825878 | ||
| 003 | DE-604 | ||
| 005 | 20200827 | ||
| 007 | t | ||
| 008 | 200728s2020 a||| |||| 00||| eng d | ||
| 020 | |a 9780128211182 |c hardback |9 978-0-12-821118-2 | ||
| 035 | |a (OCoLC)1193309716 | ||
| 035 | |a (DE-599)BVBBV046825878 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 084 | |a YG 2600 |0 (DE-625)153484:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Placebo effects in neurologic disease |c edited by Natalie P. Witek (Departement of Neurological Sciences, Rush University Medical Center, Chicago, IL, United States), Christopher G. Goetz (Departement of Neurological Sciences, Rush University Medical Center, Chicago, IL, United States), Glenn T. Stebbins (Departement of Neurological Sciences, Rush University Medical Center, Chicago, IL, United States) |
| 250 | |a First edition | ||
| 264 | 1 | |a Cambridge, MA ; San Diego, CA |b Academic Press, an imprint of Elsevier |c 2020 | |
| 300 | |a xii, 266 Seiten |b Illustrationen | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a International review of neurobiology |v volume 153 | |
| 650 | 0 | 7 | |a Placebo |0 (DE-588)4046191-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Nervenkrankheit |0 (DE-588)1068493003 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Nervenkrankheit |0 (DE-588)1068493003 |D s |
| 689 | 0 | 1 | |a Placebo |0 (DE-588)4046191-9 |D s |
| 689 | 0 | |C b |5 DE-604 | |
| 700 | 1 | |a Witek, Natalie P. |4 edt | |
| 700 | 1 | |a Goetz, Christopher G. |4 edt | |
| 700 | 1 | |a Stebbins, Glenn T. |4 edt | |
| 830 | 0 | |a International review of neurobiology |v volume 153 |w (DE-604)BV002534817 |9 153 | |
| 856 | 4 | 2 | |m Digitalisierung UB Regensburg - ADAM Catalogue Enrichment |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=032234116&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-032234116 | ||
Datensatz im Suchindex
| _version_ | 1804181642817830912 |
|---|---|
| adam_text | Contents Contributors ix Preface xi Part 1 Background and methods in placebo 1. Better than nothing: Ahistorical account of placebos and placebo effects from modern to contemporary medicine 3 Marco Annoni 1. Introduction 4 2. The etymology of placebo and its first recorded use in medicine (fourth century-1772) 5 3. Placebos as treatments In clinical practice (1772-1954) 6 4. Placebos as controls in scientific research (1772-1930s) 7 5. The Conferences on Therapy at Cornell University (1930s֊1946) 6. Beecher and the powerful placebo” (1955) 9 12 7. The rise of RCTs and the first pioneering studies on placebo effects (1955-1970s) 13 8. The empirical study of placebo effects and the golden age of placebo research (1970s-) 15 9. Summary and conclusions 22 Acknowledgment 23 References 23 2. Determinants of placebo effects 27 Sharlet Anderson and Glenn T. Stebbins 1. Introduction 27 2. Intrinsic factors impacting placebo response 30 3. Extrinsic factors impacting placebo response 38 4. Culture 40 5. Future directions 42 References 43 V
Contents VI 3. Strategies to minimize placebo effects in research investigations 49 Filipe В. Rodrigues and Joaquim J. Ferreira 1. Introduction 50 2. Concepts and definitions 50 3. Why may the placebo effect be detrimental inclinicaltrials? 52 4. The impact 54 5. Placebo effect in neurology 55 6. Strategies to minimize the placebo effect inclinical trials 57 7. Challenges and future direction 64 References 66 4. Maximizing placebo response in neurological clinical practice 71 Louise-Laure Mariani and Jean-Christophe Corvol 1. Introduction 72 2. Why should placebo bemaximized in the clinic? 73 3. How should placebo bemaximized in the clinic? 80 4. Future perspectives 90 Funding 90 Conflict of interest 90 References 91 5. Statistical methods in handling placebo effect 103 Rema Raman 1. Introduction 104 2. Trial designs 104 3. Analytical approaches 111 4. Practical considerations and recommendations 115 5. Summary 118 References 118 6. Nocebo and lessebo effects 121 Tiago A. Mestre 1. Introduction 122 2. The nocebo effect 122 3. The lessebo effect 133 4. Nocebo and lessebo effects: Impact on clinical practice and research 137
vii Contents 5. Future directions 141 References 142 7. Deception and the ethics of placebo 147 A. Jon Stoessl 1. Introduction 2. Is it necessary to include a placebo/sham group in PD research? 148 149 3. Does the scientific return justify the potential risk of a placebo/sham therapy? 150 4. Is the use of deception justifiable? 151 5. Are there alternatives to the use of deception? 153 6. Are there additional risks associated with the use of placebo/sham? 155 7. Is the use of placebo/sham therapy justifiable in clinical practice, outside a research scenario? 156 8. Conclusions 160 References 160 Part 2 Placebo response in specific disease populations 8. Placebo effects inpain 167 Luana Colloca 1. Definitions and historical notes 168 2. Scientific basis of placebo effects on pain 170 3. Clinical pain syndromes 174 4. Future directions 179 Acknowledgments 179 References 180 9. Placebo responses inParkinson s disease 187 Jau-Shin Lou 1. History: Double-blind placebo-controlled trials in Parkinson s disease (PD) 188 2. Determinants of placebo 189 3. Nocebo and lessebo responses in PD 198 4. Objective measures and markers of placebo (imaging, biologic, physiologic biomarkers) 198 5. Placebo response: Where do we go from here? 205 References 208
V||i Contents 10. Placebo effect insubjects with cognitive impairment 213 Kaori Ito and Klaus Romero 1. Introduction 214 2. Background 214 3. Failures in recent clinical trials in AD 215 4. Disease progression model in AD 217 5. Placebo response model in AD 218 6. Understanding placebo effect in AD 221 7. History of C-Path 225 8. AD disease progression model at С-Path (especially placebo response) 227 References 228 11. Placebo inepilepsy 231 Daniel M. Goldenholz and Shira R. Goldenholz 1. Introductory remarks 232 2. Basic definitions of terms 232 3. Placebo use in epilepsy 233 4. Determinants of placebo response 234 5. Modeling placebo response 242 6. Clinical observations about placebo inepilepsy 244 7. Trial design and analysis considerations 253 8. Conclusions 259 References 259
|
| adam_txt |
Contents Contributors ix Preface xi Part 1 Background and methods in placebo 1. Better than nothing: Ahistorical account of placebos and placebo effects from modern to contemporary medicine 3 Marco Annoni 1. Introduction 4 2. The etymology of "placebo" and its first recorded use in medicine (fourth century-1772) 5 3. Placebos as treatments In clinical practice (1772-1954) 6 4. Placebos as controls in scientific research (1772-1930s) 7 5. The "Conferences on Therapy" at Cornell University (1930s֊1946) 6. Beecher and the "powerful placebo” (1955) 9 12 7. The rise of RCTs and the first pioneering studies on placebo effects (1955-1970s) 13 8. The empirical study of placebo effects and the golden age of placebo research (1970s-) 15 9. Summary and conclusions 22 Acknowledgment 23 References 23 2. Determinants of placebo effects 27 Sharlet Anderson and Glenn T. Stebbins 1. Introduction 27 2. Intrinsic factors impacting placebo response 30 3. Extrinsic factors impacting placebo response 38 4. Culture 40 5. Future directions 42 References 43 V
Contents VI 3. Strategies to minimize placebo effects in research investigations 49 Filipe В. Rodrigues and Joaquim J. Ferreira 1. Introduction 50 2. Concepts and definitions 50 3. Why may the placebo effect be detrimental inclinicaltrials? 52 4. The impact 54 5. Placebo effect in neurology 55 6. Strategies to minimize the placebo effect inclinical trials 57 7. Challenges and future direction 64 References 66 4. Maximizing placebo response in neurological clinical practice 71 Louise-Laure Mariani and Jean-Christophe Corvol 1. Introduction 72 2. Why should placebo bemaximized in the clinic? 73 3. How should placebo bemaximized in the clinic? 80 4. Future perspectives 90 Funding 90 Conflict of interest 90 References 91 5. Statistical methods in handling placebo effect 103 Rema Raman 1. Introduction 104 2. Trial designs 104 3. Analytical approaches 111 4. Practical considerations and recommendations 115 5. Summary 118 References 118 6. Nocebo and lessebo effects 121 Tiago A. Mestre 1. Introduction 122 2. The nocebo effect 122 3. The lessebo effect 133 4. Nocebo and lessebo effects: Impact on clinical practice and research 137
vii Contents 5. Future directions 141 References 142 7. Deception and the ethics of placebo 147 A. Jon Stoessl 1. Introduction 2. Is it necessary to include a placebo/sham group in PD research? 148 149 3. Does the scientific return justify the potential risk of a placebo/sham therapy? 150 4. Is the use of deception justifiable? 151 5. Are there alternatives to the use of deception? 153 6. Are there additional risks associated with the use of placebo/sham? 155 7. Is the use of placebo/sham therapy justifiable in clinical practice, outside a research scenario? 156 8. Conclusions 160 References 160 Part 2 Placebo response in specific disease populations 8. Placebo effects inpain 167 Luana Colloca 1. Definitions and historical notes 168 2. Scientific basis of placebo effects on pain 170 3. Clinical pain syndromes 174 4. Future directions 179 Acknowledgments 179 References 180 9. Placebo responses inParkinson's disease 187 Jau-Shin Lou 1. History: Double-blind placebo-controlled trials in Parkinson's disease (PD) 188 2. Determinants of placebo 189 3. Nocebo and lessebo responses in PD 198 4. Objective measures and markers of placebo (imaging, biologic, physiologic biomarkers) 198 5. Placebo response: Where do we go from here? 205 References 208
V||i Contents 10. Placebo effect insubjects with cognitive impairment 213 Kaori Ito and Klaus Romero 1. Introduction 214 2. Background 214 3. Failures in recent clinical trials in AD 215 4. Disease progression model in AD 217 5. Placebo response model in AD 218 6. Understanding placebo effect in AD 221 7. History of C-Path 225 8. AD disease progression model at С-Path (especially placebo response) 227 References 228 11. Placebo inepilepsy 231 Daniel M. Goldenholz and Shira R. Goldenholz 1. Introductory remarks 232 2. Basic definitions of terms 232 3. Placebo use in epilepsy 233 4. Determinants of placebo response 234 5. Modeling placebo response 242 6. Clinical observations about placebo inepilepsy 244 7. Trial design and analysis considerations 253 8. Conclusions 259 References 259 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author2 | Witek, Natalie P. Goetz, Christopher G. Stebbins, Glenn T. |
| author2_role | edt edt edt |
| author2_variant | n p w np npw c g g cg cgg g t s gt gts |
| author_facet | Witek, Natalie P. Goetz, Christopher G. Stebbins, Glenn T. |
| building | Verbundindex |
| bvnumber | BV046825878 |
| classification_rvk | YG 2600 |
| ctrlnum | (OCoLC)1193309716 (DE-599)BVBBV046825878 |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| edition | First edition |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02036nam a2200409 cb4500</leader><controlfield tag="001">BV046825878</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20200827 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">200728s2020 a||| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780128211182</subfield><subfield code="c">hardback</subfield><subfield code="9">978-0-12-821118-2</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1193309716</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046825878</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YG 2600</subfield><subfield code="0">(DE-625)153484:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Placebo effects in neurologic disease</subfield><subfield code="c">edited by Natalie P. Witek (Departement of Neurological Sciences, Rush University Medical Center, Chicago, IL, United States), Christopher G. Goetz (Departement of Neurological Sciences, Rush University Medical Center, Chicago, IL, United States), Glenn T. Stebbins (Departement of Neurological Sciences, Rush University Medical Center, Chicago, IL, United States)</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">First edition</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cambridge, MA ; San Diego, CA</subfield><subfield code="b">Academic Press, an imprint of Elsevier</subfield><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">xii, 266 Seiten</subfield><subfield code="b">Illustrationen</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">International review of neurobiology</subfield><subfield code="v">volume 153</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Placebo</subfield><subfield code="0">(DE-588)4046191-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Nervenkrankheit</subfield><subfield code="0">(DE-588)1068493003</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Nervenkrankheit</subfield><subfield code="0">(DE-588)1068493003</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Placebo</subfield><subfield code="0">(DE-588)4046191-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="C">b</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Witek, Natalie P.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Goetz, Christopher G.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stebbins, Glenn T.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">International review of neurobiology</subfield><subfield code="v">volume 153</subfield><subfield code="w">(DE-604)BV002534817</subfield><subfield code="9">153</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Regensburg - ADAM Catalogue Enrichment</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=032234116&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-032234116</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV046825878 |
| illustrated | Illustrated |
| index_date | 2024-07-03T15:03:34Z |
| indexdate | 2024-07-10T08:54:54Z |
| institution | BVB |
| isbn | 9780128211182 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-032234116 |
| oclc_num | 1193309716 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | xii, 266 Seiten Illustrationen |
| publishDate | 2020 |
| publishDateSearch | 2020 |
| publishDateSort | 2020 |
| publisher | Academic Press, an imprint of Elsevier |
| record_format | marc |
| series | International review of neurobiology |
| series2 | International review of neurobiology |
| spelling | Placebo effects in neurologic disease edited by Natalie P. Witek (Departement of Neurological Sciences, Rush University Medical Center, Chicago, IL, United States), Christopher G. Goetz (Departement of Neurological Sciences, Rush University Medical Center, Chicago, IL, United States), Glenn T. Stebbins (Departement of Neurological Sciences, Rush University Medical Center, Chicago, IL, United States) First edition Cambridge, MA ; San Diego, CA Academic Press, an imprint of Elsevier 2020 xii, 266 Seiten Illustrationen txt rdacontent n rdamedia nc rdacarrier International review of neurobiology volume 153 Placebo (DE-588)4046191-9 gnd rswk-swf Nervenkrankheit (DE-588)1068493003 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Nervenkrankheit (DE-588)1068493003 s Placebo (DE-588)4046191-9 s b DE-604 Witek, Natalie P. edt Goetz, Christopher G. edt Stebbins, Glenn T. edt International review of neurobiology volume 153 (DE-604)BV002534817 153 Digitalisierung UB Regensburg - ADAM Catalogue Enrichment application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=032234116&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Placebo effects in neurologic disease International review of neurobiology Placebo (DE-588)4046191-9 gnd Nervenkrankheit (DE-588)1068493003 gnd |
| subject_GND | (DE-588)4046191-9 (DE-588)1068493003 (DE-588)4143413-4 |
| title | Placebo effects in neurologic disease |
| title_auth | Placebo effects in neurologic disease |
| title_exact_search | Placebo effects in neurologic disease |
| title_exact_search_txtP | Placebo effects in neurologic disease |
| title_full | Placebo effects in neurologic disease edited by Natalie P. Witek (Departement of Neurological Sciences, Rush University Medical Center, Chicago, IL, United States), Christopher G. Goetz (Departement of Neurological Sciences, Rush University Medical Center, Chicago, IL, United States), Glenn T. Stebbins (Departement of Neurological Sciences, Rush University Medical Center, Chicago, IL, United States) |
| title_fullStr | Placebo effects in neurologic disease edited by Natalie P. Witek (Departement of Neurological Sciences, Rush University Medical Center, Chicago, IL, United States), Christopher G. Goetz (Departement of Neurological Sciences, Rush University Medical Center, Chicago, IL, United States), Glenn T. Stebbins (Departement of Neurological Sciences, Rush University Medical Center, Chicago, IL, United States) |
| title_full_unstemmed | Placebo effects in neurologic disease edited by Natalie P. Witek (Departement of Neurological Sciences, Rush University Medical Center, Chicago, IL, United States), Christopher G. Goetz (Departement of Neurological Sciences, Rush University Medical Center, Chicago, IL, United States), Glenn T. Stebbins (Departement of Neurological Sciences, Rush University Medical Center, Chicago, IL, United States) |
| title_short | Placebo effects in neurologic disease |
| title_sort | placebo effects in neurologic disease |
| topic | Placebo (DE-588)4046191-9 gnd Nervenkrankheit (DE-588)1068493003 gnd |
| topic_facet | Placebo Nervenkrankheit Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=032234116&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV002534817 |
| work_keys_str_mv | AT witeknataliep placeboeffectsinneurologicdisease AT goetzchristopherg placeboeffectsinneurologicdisease AT stebbinsglennt placeboeffectsinneurologicdisease |